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Background
Cardiorenal syndrome (CRS) is characterized by neurohu-
moral activation, sodium retention, ventricular dysfunc-
tion and congestion, and renal insufficiency (RI). The
congestive heart failure (CHF) component evolves from
asymptomatic, to stable symptomatic to overt sympto-
matic CHF. The natriuretic peptide system (NPS), includ-
ing atrial (ANP) and brain (BNP) natriuretic peptides is
progressively activated during progression of CHF. Less is
known about the second messenger, cGMP, of the NPS
across the spectrum of CHF. RI in CHF remains an impor-
tant clinical challenge and Cystatin C is emerging as an
important marker of RI. Further work is needed in charac-
terizing Cystatin C across the spectrum of CHF and CRS.
Methods
We prospectively looked at the NPS, including ANP, NT-
proANP, BNP, and NT-proBNP, as well as plasma cGMP,
NPS to cGMP ratios and Cystatin C in three groups of sub-
jects: normal volunteers (n = 10), stable CHF patients (n
= 19), and higher risk CHF patients (based on recent hos-
pitalization for CHF, n = 20). The groups are reported in
that order below. Statistical analysis was carried out by
ANOVA with p < 0.05 accepted as significant (*).
Results
Each component of the NPS increased in the plasma
across the three groups with highest levels in the high risk
CHF. However, cGMP levels did not vary significantly
across groups (626 ± 303 vs 914 ± 521 vs 959 ± 509 pmol/
mL, NS). The ratio NT-proANP/cGMP increased across the
3 groups (0.60 ± 0.55 vs 1.02 ± 0.52 vs 1.46 ± 1.08,*), but
the ratios of ANP/cGMP, BNP/cGMP, and NT-proBNP/
cGMP did not vary significantly across groups. Impor-
tantly, the mean Cystatin C levels increased with stable
and high risk CHF groups (0.9 ± 0.1 vs 1.4 ± 0.3 vs 1.8 ±
0.7,*).
Conclusion
Despite the increase of each component of the NPS meas-
ured in the stable and high risk CHF, cGMP did not
increase significantly across the same groups. Except for
the ratio NT-proANP/cGMP, the ratios of the NPS to
cGMP did not vary across groups either, suggesting the
need to further refine our understanding of the coupling
of the NPS with its second messenger, cGMP. Importantly,
we report for the first time that Cystatin C varies across
these phenotypes of CHF, suggesting that it may be an
important marker of the development of CRS.
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